Here's Why the Slump in Danaher Stock This Week Looks Like a Buying Opportunity

Management raised full-year guidance, but nearly all of it hinges on an acquisition. The reduction in full-year sales growth guidance in biotechnology is likely due to shipment lumpiness.

The Motley Fool • 6 hours ago

The 'Standout Performance' That Could Save Thermo Fisher, Danaher And Others

Thermo Fisher stock led a medtech rebound Thursday, easing investors' fears of continued malaise for the medical research and tools realm.

Investors Business Daily • Jul 23, 2026

Don't Quit on Danaher Stock After Horrific Earnings Reaction

There's reason to believe the stock can stage a comeback after its worst day in two decades.

Barrons • Jul 22, 2026

Can Danaher (DHR) Climb 32.39% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 32.4% in Danaher (DHR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research • Jul 22, 2026

Stock Of The Day: Is The Danaher Selloff Over?

Danaher Corporation  (NYSE:DHR) is consolidating on Wednesday. The shares plunged by more than 10% yesterday, with the move driven by a weak earnings report.

Benzinga • Jul 22, 2026

Danaher's revenue outlook cut, biotech miss overshadow profit forecast raise

Danaher raised its annual profit forecast on Tuesday, but shares fell nearly 12% in premarket trading after the life sciences firm ​trimmed its core revenue growth outlook and reported weaker-than-expected revenue ‌in its biotechnology business.

Reuters • Jul 21, 2026

Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 1% on Tuesday.

Benzinga • Jul 21, 2026

Danaher Plummets After One Segment Comes In 'Surprisingly Soft'

Danaher stock plummeted Tuesday after reporting what one analyst called "surprisingly soft" bioprocessing sales.

Investors Business Daily • Jul 21, 2026

Danaher Q2 Earnings Call Highlights

Danaher NYSE: DHR reported better-than-expected second-quarter 2026 results, with management citing accelerating core revenue growth, stronger life sciences demand and benefits from productivity initiatives, while also addressing investor concerns over delayed bioprocessing shipments.

MarketBeat • Jul 21, 2026

Danaher Q2 Earnings Review: Nothing Exciting For Me To Buy This Dip

Danaher Corporation delivered Q2 revenue of $6.3B (+5.5% y/y), beating estimates and showing segment growth across Biotechnology, Diagnostics, and Life Sciences. Gross margins declined due to higher cost of sales, but operating margins improved significantly on tight SG&A control and DBS-driven productivity. Management raised full-year EPS guidance slightly, but projected low single-digit revenue growth and a slow recovery, disappointing investors and triggering a 14% share price drop.

Seeking Alpha • Jul 21, 2026